BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38073694)

  • 1. Appropriate leucine-rich α-2 glycoprotein cut-off value for Japanese patients with ulcerative colitis.
    Yamazato M; Yanai S; Oizumi T; Eizuka M; Yamada S; Toya Y; Uesugi N; Sugai T; Matsumoto T
    World J Clin Cases; 2023 Nov; 11(32):7753-7760. PubMed ID: 38073694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.
    Urushikubo J; Yanai S; Nakamura S; Kawasaki K; Akasaka R; Sato K; Toya Y; Asakura K; Gonai T; Sugai T; Matsumoto T
    World J Gastroenterol; 2018 Oct; 24(38):4384-4392. PubMed ID: 30344422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.
    Shimoyama T; Yamamoto T; Yoshiyama S; Nishikawa R; Umegae S
    Inflamm Bowel Dis; 2023 Sep; 29(9):1399-1408. PubMed ID: 36334015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Utility of Leucine-Rich Alpha-2-Glycoprotein as a Biomarker in Ulcerative Colitis: A Predictor of Endoscopic Remission Independent of Symptoms.
    Hayashi T; Kitamura K; Usami M; Miyazawa M; Nishitani M; Dejima A; Yamamoto M; Kawase S; Funaki M; Orita N; Nakagawa H; Morita K; Iida N; Seki A; Nio K; Kido H; Takayama H; Takeuchi Y; Yamada S; Takatori H; Shimada M; Saito H; Yamamoto D; Toyama T; Yamashita T
    Inflamm Intest Dis; 2023 Dec; 8(4):133-142. PubMed ID: 38115911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of plasma alternative to serum for measuring leucine-rich α2-glycoprotein as a biomarker of inflammatory bowel disease.
    Ichimiya T; Kazama T; Ishigami K; Yokoyama Y; Hayashi Y; Takahashi S; Itoi T; Nakase H
    PLoS One; 2023; 18(6):e0286415. PubMed ID: 37352151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leucine-Rich Alpha-2 Glycoprotein in Monitoring Disease Activity and Intestinal Stenosis in Inflammatory Bowel Disease.
    Yoshida T; Shimodaira Y; Fukuda S; Watanabe N; Koizumi S; Matsuhashi T; Onochi K; Iijima K
    Tohoku J Exp Med; 2022 Jul; 257(4):301-308. PubMed ID: 35598974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early change in serum leucine-rich α-2-glycoprotein predicts clinical and endoscopic response in ulcerative colitis.
    Karashima R; Sagami S; Yamana Y; Maeda M; Hojo A; Miyatani Y; Nakano M; Matsuda T; Hibi T; Kobayashi T
    Intest Res; 2024 Jun; ():. PubMed ID: 38835140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study.
    Shinzaki S; Matsuoka K; Tanaka H; Takeshima F; Kato S; Torisu T; Ohta Y; Watanabe K; Nakamura S; Yoshimura N; Kobayashi T; Shiotani A; Hirai F; Hiraoka S; Watanabe M; Matsuura M; Nishimoto S; Mizuno S; Iijima H; Takehara T; Naka T; Kanai T; Matsumoto T
    J Gastroenterol; 2021 Jun; 56(6):560-569. PubMed ID: 33942166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Leucine-Rich α2 Glycoprotein: A Biomarker for Predicting the Presence of Ulcerative Colitis but Not Ulcerative Proctitis.
    Horiuchi I; Horiuchi A; Umemura T
    J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis.
    Shinzaki S; Matsuoka K; Iijima H; Mizuno S; Serada S; Fujimoto M; Arai N; Koyama N; Morii E; Watanabe M; Hibi T; Kanai T; Takehara T; Naka T
    J Crohns Colitis; 2017 Jan; 11(1):84-91. PubMed ID: 27466171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of the Optimal Cutoff Value and Delta Value of Leucine-Rich Alpha 2 Glycoprotein in Ulcerative Colitis.
    Matsumoto S; Mashima H
    Crohns Colitis 360; 2022 Oct; 4(4):otac039. PubMed ID: 36778513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease.
    Yoshimura T; Mitsuyama K; Sakemi R; Takedatsu H; Yoshioka S; Kuwaki K; Mori A; Fukunaga S; Araki T; Morita M; Tsuruta K; Yamasaki H; Torimura T
    Mediators Inflamm; 2021; 2021():8825374. PubMed ID: 33623482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum leucine-rich alpha-2 glycoprotein in monitoring disease activity and intestinal mucosal healing for biotherapy-naïve cases with ulcerative colitis.
    Kono M; Komeda Y; Tribonias G; Yoshida S; Nomura K; Handa K; Nagai T; Hagiwara S; Omoto S; Takenaka M; Nishida N; Tsuji N; Kashida H; Kudo M
    JGH Open; 2023 Aug; 7(8):579-583. PubMed ID: 37649867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What is the appropriate cut-off value of CRP to predict endoscopic remission in patients with ulcerative colitis in clinical remission?
    Shin J; Kong SM; Seong G; Kim YH
    Int J Colorectal Dis; 2020 Dec; 35(12):2249-2255. PubMed ID: 32749515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis.
    Serada S; Fujimoto M; Terabe F; Iijima H; Shinzaki S; Matsuzaki S; Ohkawara T; Nezu R; Nakajima S; Kobayashi T; Plevy SE; Takehara T; Naka T
    Inflamm Bowel Dis; 2012 Nov; 18(11):2169-79. PubMed ID: 22374925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum leucine-rich alpha-2 glycoprotein and calprotectin in children with inflammatory bowel disease: A multicenter study in Japan.
    Yasuda R; Arai K; Kudo T; Nambu R; Aomatsu T; Abe N; Kakiuchi T; Hashimoto K; Sogo T; Takahashi M; Etani Y; Kato K; Yamashita Y; Mitsuyama K; Mizuochi T
    J Gastroenterol Hepatol; 2023 Jul; 38(7):1131-1139. PubMed ID: 36880154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease.
    Yasutomi E; Inokuchi T; Hiraoka S; Takei K; Igawa S; Yamamoto S; Ohmori M; Oka S; Yamasaki Y; Kinugasa H; Takahara M; Harada K; Furukawa M; Itoshima K; Okada K; Otsuka F; Tanaka T; Mitsuhashi T; Kato J; Okada H
    Sci Rep; 2021 May; 11(1):11086. PubMed ID: 34045529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers for Monitoring of Changes in Disease Activity in Ulcerative Colitis.
    Tatsumi Y; Kakimoto K; Hara A; Mizuta N; Numa K; Kinoshita N; Nakazawa K; Koshiba R; Hirata Y; Ota K; Miyazaki T; Nakamura S; Sakagami K; Arimitsu S; Ito H; Nishikawa H
    J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of Serum Leucine-Rich Alpha-2 Glycoprotein in Evaluating Endoscopic Disease Activity in Crohn's Disease.
    Kawamura T; Yamamura T; Nakamura M; Maeda K; Sawada T; Ishikawa E; Iida T; Mizutani Y; Ishikawa T; Kakushima N; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M
    Inflamm Bowel Dis; 2023 Feb; 29(2):245-253. PubMed ID: 35436345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis.
    Lee SH; Kim MJ; Chang K; Song EM; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
    BMC Gastroenterol; 2017 Oct; 17(1):110. PubMed ID: 29061121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.